| Primary |
| Cystic Fibrosis |
44.6% |
| Product Used For Unknown Indication |
25.3% |
| Drug Use For Unknown Indication |
18.0% |
| Pleural Infection |
1.9% |
| Cystic Fibrosis Pancreatic |
1.3% |
| Diabetes Mellitus |
1.3% |
| Asthma |
0.9% |
| Infective Pulmonary Exacerbation Of Cystic Fibrosis |
0.9% |
| Cystic Fibrosis Lung |
0.7% |
| Pancreatic Insufficiency |
0.7% |
| Bronchopulmonary Aspergillosis Allergic |
0.6% |
| Lung Infection |
0.6% |
| Pneumonia |
0.6% |
| Rhinitis Allergic |
0.6% |
| Sepsis |
0.6% |
| Atelectasis |
0.3% |
| Chronic Obstructive Pulmonary Disease |
0.3% |
| Fibrosis |
0.3% |
| Hypotension |
0.3% |
| Lung Disorder |
0.3% |
|
| Pneumonia |
31.9% |
| Death |
24.4% |
| Haemoptysis |
7.1% |
| Pyrexia |
5.9% |
| Dyspnoea |
3.5% |
| Weight Decreased |
3.5% |
| Cough |
2.8% |
| Vomiting |
2.8% |
| Pulmonary Haemorrhage |
2.4% |
| Cystic Fibrosis |
2.0% |
| Disease Progression |
1.6% |
| Lung Infection |
1.6% |
| Pulmonary Function Test Decreased |
1.6% |
| Respiratory Failure |
1.6% |
| Tonsillitis |
1.6% |
| Abdominal Pain |
1.2% |
| Bronchitis |
1.2% |
| Cardiopulmonary Failure |
1.2% |
| Chest Pain |
1.2% |
| Diarrhoea |
1.2% |
|
| Secondary |
| Drug Use For Unknown Indication |
44.9% |
| Cystic Fibrosis |
15.7% |
| Product Used For Unknown Indication |
7.0% |
| Asthma |
5.9% |
| Cystic Fibrosis Pancreatic |
5.4% |
| Diabetes Mellitus |
4.9% |
| Bronchopulmonary Aspergillosis Allergic |
2.7% |
| Bronchitis |
2.2% |
| Fibrinous Bronchitis |
2.2% |
| Pleural Infection |
2.2% |
| Pneumonia |
1.1% |
| Pneumothorax |
1.1% |
| Pulmonary Embolism |
1.1% |
| Bronchial Disorder |
0.5% |
| Endotracheal Intubation |
0.5% |
| Increased Bronchial Secretion |
0.5% |
| Inflammation |
0.5% |
| Portal Hypertension |
0.5% |
| Pseudomonas Infection |
0.5% |
| Viral Infection |
0.5% |
|
| Death |
21.4% |
| Haemoptysis |
11.9% |
| Vomiting |
9.5% |
| Weight Decreased |
9.5% |
| Cystic Fibrosis |
4.8% |
| Infection |
4.8% |
| Pneumothorax |
4.8% |
| Stenotrophomonas Infection |
4.8% |
| Urticaria |
4.8% |
| Cough |
2.4% |
| Drug Ineffective |
2.4% |
| Peritonitis |
2.4% |
| Rash |
2.4% |
| Renal Failure |
2.4% |
| Respiratory Failure |
2.4% |
| Sinus Congestion |
2.4% |
| Sleep Disorder |
2.4% |
| Tinnitus |
2.4% |
| Vulvovaginal Candidiasis |
2.4% |
|
| Concomitant |
| Cystic Fibrosis |
35.9% |
| Product Used For Unknown Indication |
17.7% |
| Drug Use For Unknown Indication |
8.5% |
| Cystic Fibrosis Lung |
6.2% |
| Asthma |
5.6% |
| Pseudomonas Infection |
4.8% |
| Pancreatic Insufficiency |
3.6% |
| Gastrooesophageal Reflux Disease |
3.4% |
| Pain |
2.1% |
| Convulsion |
1.8% |
| Infective Pulmonary Exacerbation Of Cystic Fibrosis |
1.6% |
| Medical Diet |
1.3% |
| Lung Disorder |
1.3% |
| Constipation |
1.2% |
| Anticoagulant Therapy |
1.0% |
| Cough |
1.0% |
| Malabsorption |
0.9% |
| Bronchial Hyperreactivity |
0.8% |
| Prophylaxis |
0.7% |
| Upper Respiratory Tract Infection |
0.7% |
|
| Upper Respiratory Tract Infection |
15.9% |
| Infective Pulmonary Exacerbation Of Cystic Fibrosis |
13.3% |
| Death |
6.8% |
| Pneumonia |
6.8% |
| Pseudomonas Infection |
6.5% |
| Lung Infection |
5.9% |
| Staphylococcal Infection |
4.7% |
| Pyrexia |
4.4% |
| Infection |
4.1% |
| Lung Disorder |
4.1% |
| Vomiting |
4.1% |
| Respiratory Failure |
3.2% |
| Haemoptysis |
2.9% |
| Wheezing |
2.9% |
| Dyspnoea |
2.7% |
| Weight Decreased |
2.7% |
| Pneumothorax |
2.4% |
| Pulmonary Function Test Decreased |
2.4% |
| Constipation |
2.1% |
| Malaise |
2.1% |
|
